# AstriVax

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/astrivax

- Industry: Biotechnology
- Headquarters: Heverlee, Belgium
- Website: https://astrivax.com
- Total disclosed funding: $10M
- Latest round: Seed (Aug 16, 2022)
- Investors on record: 8

## About

Based in Belgium, and founded in 2022, AstriVax operates as a vaccine technology company. The company was founded by its CEO, Hanne Callewaert,  Johan Neyts, and Kai Dallmeier. In December 2023, AstriVax received EUR 3 million in grant funding from Agentschap Innoveren & Ondernemen.

AstriVax offers a PLLAV platform, which is a plasmid-launched live attenuated virus technology that engages in the production of thermostable infectious vaccines. The company’s portfolio develops prophylactic vaccines and therapeutic vaccines through its pipeline technology. These vaccines can be used to protect against several illnesses, including chronic hepatitis B, rabies, and yellow fever.

The company plans to use the funds raised in December 2023 to ramp up the development of its vaccine for Hepatitis B.

## Funding rounds

- Seed, Aug 16, 2022, $10M — K.U. Leuven Research & Development, BNP Paribas Asset Management - Fund of funds, Thuja Capital, Ackermans & van Haaren, Fund+, V-Bio Ventures, Merieux Equity Partners, Flanders Future Techfund

## Investors

- K.U. Leuven Research & Development (https://capitalatlas.ai/funds/k-u-leuven-research-development) — Seed
- BNP Paribas Asset Management - Fund of funds (https://capitalatlas.ai/funds/bnp-paribas-asset-management-fund-of-funds) — Seed
- Thuja Capital (https://capitalatlas.ai/funds/thuja-capital) — Seed
- Ackermans & van Haaren (https://capitalatlas.ai/funds/ackermans-van-haaren) — Seed
- Fund+ (https://capitalatlas.ai/funds/fund) — Seed
- V-Bio Ventures (https://capitalatlas.ai/funds/v-bio-ventures) — Seed
- Merieux Equity Partners (https://capitalatlas.ai/funds/merieux-equity-partners) — Seed
- Flanders Future Techfund — Seed